皮下与静脉内部的托西利祖马布在动脉炎中与巨细胞动脉炎相关:对196名患者的多中心研究
Carmen Secada-Gómez1, Javier Loricera1, Adrián-Martín Gutiérrez1
1Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology group, Santander, Cantabria, Spain.
Arthritis care & research
|January 14, 2026
概括
皮下托西利祖马布 (TCZ) 与静脉注射TCZ相比,在巨细胞动脉炎 (GCA) 相关的动脉炎中略有改善了EULAR缓解. 在这个现实研究中,IV和SCTCZ组的成像缓解率在IV和SCTCZ组之间是相似的.
科学领域:
- 类风湿病学 类风湿病学
- 血管炎症 血管炎症
- 免疫抑制疗法 免疫抑制疗法
背景情况:
- 巨细胞动脉炎 (GCA) 可以导致严重的动脉炎,导致诸如动脉瘤等并发症.
- 托西利祖马布 (TCZ) 对GCA是有效的,但其基于给药途径 (IV与SC) 的对主动脉炎的比较疗效尚不清楚.
研究的目的:
- 在现实临床条件下,比较静脉注射 (IV) 与皮下注射 (SC) 托西利祖马布 (TCZ) 在GCA相关的风炎患者的疗效.
主要方法:
- 一项多中心观察性研究包括196名通过成像诊断的与GCA相关的关节炎患者,并用TCZ治疗.
- 患者根据TCZ的服用途径进行分类:IV或SC.
- 评估的结果包括EULAR缓解,临床和成像缓解,全身炎症的缺失,以及糖皮质激素节约作用.
主要成果:
- 在IV和SC TCZ组之间没有在基线特征或炎症标志物中发现显著差异.
- 在IV和SC TCZ组之间,葡萄糖皮质激素节约效应是可比的.
- 在24个月后,在SC TCZ组 (83.3%) 和IV TCZ组 (80.6%) 中,EULAR定义的缓解更频繁,尽管成像缓解和缺乏系统性炎症是相似的.
结论:
- 皮下TCZ在实现EULAR定义的缓解中表现出略高的有效性,与IVTCZ相比,在现实环境中实现了与GCA相关的关节炎的EULAR定义的缓解.
- 在GCA相关的风炎的IV和SC TCZ给药途径之间没有观察到成像缓解的显著差异.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
484
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
484
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
429
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
429
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
483
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
483
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
476
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
476
Myocarditis III: Medical Management
173
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
173
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
232
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
232


